Showing results (51-60 of 85) with videos related to
Sort By:
Pageof 9
JTO Clinical and Research Reports|January 19, 2023
Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained SettingsAkhil Kapoor, Vanita Noronha, Vijay Patil, et al.South Asian Journal of Cancer|December 31, 2025
Safety and Efficacy of Alectinib in the First Line for ALK-Mutated Lung Cancer: A Real-World Data from IndiaAjaykumar Singh, Vanita Noronha, Vijay Patil, et al.Ecancermedicalscience|March 8, 2021
Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastomaGunjesh Kumar, Hollis DSouza, Nandini Menon, et al.Journal of Adolescent and Young Adult Oncology|July 25, 2020
High Response Rates and Promising Outcomes of Patients with Relapsed Ewing Sarcoma, Especially in Adolescents and Young Adults Treated on a Novel Hybrid Salvage Chemotherapy RegimenKalasekhar Vijayasekharan, Subramaniam Ramanathan, Girish Chinnaswamy, et al.Ecancermedicalscience|March 5, 2024
Clinical characteristics, outcomes and prognostic factors in KRAS mutant lung cancers: experience from a tertiary care cancer center in IndiaVanita Noronha, Laboni Sarkar, Vijay Patil, et al.Annals of Diagnostic Pathology|March 6, 2024
SALTT study: A retrospective analysis of 111 SAlivary gland tumors of Lung and Tracheobronchial TreeNishtha Batra, Prabhashankar Mishra, Trupti Pai, et al.Cancer Medicine|May 14, 2020
Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade gliomaVijay M Patil, Arti Bhelekar, Nandini Menon, et al.Journal of Gastrointestinal Cancer|November 23, 2022
Epidemiological Trend of Esophageal Cancer at a Tertiary Cancer Center in Mumbai, India, Over the Past 15 YearsVanita Noronha, Anbarasan Sekar, Akhil Rajendra, et al.Indian Journal of Cancer|August 28, 2018
Analysis of bone and soft-tissue sarcomas registered during the year 2012 at Tata Memorial Hospital, Mumbai, with clinical outcomesJyoti Bajpai, Nehal Khanna, Tushar Vora, et al.Oncotarget|November 8, 2019
Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancerVijay Patil, Amit Joshi, Vanita Noronha, et al.Pageof 9